YahooAugust 6, 2026 at 9:03 PM NY28 days ago

CytomX Therapeutics Q2 Earnings Call Highlights

CytomX Therapeutics (NASDAQ:CTMX) said its second-quarter focus remained on advancing Varseta-M, an EpCAM-targeting antibody-drug conjugate being developed for metastatic colorectal cancer, while expanding the program into combination regimens and additional gastrointestinal cancers. Chief Executiv

Read the Full Story at the Source

The summary here comes from the news provider; the rest of the article lives on the publisher's site — Yahoo

Read at Source

Companies in This Story

CTMXCytomX Therapeutics Inc3.71+ 0.82%

Companies in This Story

Related Stories